

Special Issue

Innovative Therapeutics and Biomarkers in Hepatocellular Carcinoma Research

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is still a leading cause of cancer that is associated with mortalities. It continues to compel innovations and advancements in biomarker identification and therapeutic approaches. This Special Issue will act as the foundation for innovations made in the field of HCC to address obstacles and challenges of its early diagnosis, effective management, and personalized medicine. We invite original research, systematic reviews, meta-analyses of clinical trials and reviews exploring novel diagnostic biomarkers for early diagnosis and prognosis, along with innovative therapeutics approaches. This Special Issue aims to foster multidisciplinary and interdisciplinary collaboration among physicians, scientists and manufacturers to improve patient-oriented outcomes and translational research. Submissions highlighting molecular mechanisms, engineering approaches, innovative imaging approaches and AI-driven insights are especially encouraged.

Guest Editor

Prof. Dr. Alok Raghav

Department of Anatomy and Cell Biology, College of Medicine, Gachon University, Incheon, Republic of Korea

Deadline for manuscript submissions

20 January 2026



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/226192

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and
other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 17.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names are published annually in the journal.